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Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y1 and P2Y14 receptors in mice.
Introduction Platelet activation has been described in patients with chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), Inflammatory bowel disease (IBS), rheumatoid arthritis (RA), asthma and allergies, and in patients suffering from infectious diseases [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . A number in vivo studies have previously demonstrated the presence of platelet activation through the upregulation of P-selectin expression, the formation of platelet-leukocyte conjugates and the release of pro-inflammatory mediators in septic, allergic, and sterile inflammation. These studies also demonstrate the importance of platelets for leukocyte recruitment [3, [11] [12] [13] [14] .
The role of platelet purinergic receptors in the context of platelet aggregation has been well documented with co-stimulation of the P2Y1 and P2Y12 receptors by ADP, and following ATP stimulation of the P2X1 receptor [15] [16] [17] [18] [19] [20] [21] [22] . Furthermore, a number of studies have detailed the ability of purinergic receptor stimulation to induce increases in P-selectin expression and the incidence of platelet-leukocyte conjugates which are considered to be a prerequisite for leukocyte recruitment [23] [24] [25] . Using a murine model of allergic airway inflammation we have previously demonstrated that pulmonary leukocyte recruitment was mediated via RhoA signalling downstream of the platelet P2Y1 receptor, whilst the P2Y12 and P2X1 receptors showed no involvement in this process [26] . More recently, platelets have been shown to express the P2Y14 receptor on their surface [27] . However, the P2Y14 receptor appears to be redundant in platelet aggregation, whilst demonstrating an ability to mediate cell migration in other cell types [27] [28] [29] [30] . A physiological role for platelet P2Y14 receptor activation therefore remains unknown in the context of host defence and inflammation. The aim of the present study was therefore to characterise the role of the P2Y1, P2Y12, P2Y14 and P2X1 receptors in a murine model of LPS induced pulmonary inflammation which we and others have reported to be dependent on platelet activation.
Methods

Materials
PGE1, lipopolysaccharide (LPS, extracted from Escherichia Coli O55:B5 serotype), Ticagrelor
adenosine-diphosphate (ADP) were purchased from Sigma (Poole, UK); MRS2179 (N 6 -methyl- lavage fluid was collected and processed for total and differential cell counts as previously described [11, 26, 31] . Circulating platelet numbers were enumerated at 4 hours post LPS challenge after blood was taken via cardiac puncture, and quantified in stromatol (1:100 dilution) on an Improved Neubauer haemocytometer using an Axioskop Microscope under an x40 objective.
Platelet aggregation
Blood from mice was collected by means of cardiac puncture 1 hour post LPS challenge and washed platelets isolated to confirm biological activity and to compare the effects on haemostasis of P2Y1, P2Y12, P2Y14 and P2X1 antagonists described above. Platelet aggregation was measured after stimulation with 10µmol/L ADP as previously described [26] . Platelet aggregation towards UDP-glucose (agonist for P2Y14) was also assessed at increasing concentrations to 1µmol/L.
Bleeding times
Animals were kept under continuous anaesthesia with inhaled isoflurane anaesthetic.
Bleeding assays were performed 1 hour post LPS challenge in mice by tail tip amputation, immersing the tail in saline at 37°C and continuously monitoring bleeding patterns. Each animal was monitored for up to 10 minutes and bleeding times determined using a stop clock.
At the conclusion of the experiment, animals were killed with an overdose of anaesthetic.
Platelet-induced leukocyte chemotaxis
An in vitro assay of platelet-dependent leukocyte chemotaxis was used to elucidate the importance of each of the 4 purinergic receptors expressed on platelets on subsequent leukocyte activation as previously described [26] . Chemotaxis plates (3µm pore size) were blocked with Tyrode's buffer with 1% BSA for 1 hour. After blocking, the blocking buffer was removed and replaced with 100nmol/L macrophage-derived chemokine (MDC). Washed platelets at a concentration of 1x10 8 platelets/ml were prepared from whole blood as previously described [26] and were incubated with either the P2Y1, P2Y12 and P2X1 antagonists MRS2500, AR-C66096 and NF-279 (1-1000nmol/L) respectively, or the P2Y14 receptor agonists UDP-glucose (1-1000nmol/L) or MRS2690 (10-1000nmol/L) for 10 minutes at room temperature. Platelets treated with either MRS2500, AR-C66096 and NF-279 were stimulated with 100nmol/L ADP for 5 minutes, and then washed. Leukocytes were flushed from bone marrow (femurs) of mice and resuspended in a Dulbecco modified Eagle medium based assay buffer to a concentration of 5x10 6 leukocytes/ml. Leukocytes were then added to platelets at a 1:1 volumetric ratio and the chemotaxis assay performed as previously described [12] .
Statistical Analysis
Data from in vivo animal studies are displayed as means ± SEMs, whilst in vitro chemotaxis data are displayed as a chemotactic index. Data were analysed by means of 1-way ANOVA, followed by the Bonferroni multiple comparison post-test. A P value of less than 0.05 was considered significant.
Results
Activation of P2Y1 and P2Y14 but not P2Y12 or P2X1 receptors, is necessary for pulmonary leukocyte recruitment in a murine model of LPS induced inflammation
Exposure to 1.25mg/kg LPS induced a significant increase in total pulmonary leukocyte recruitment (P <0.001, Fig 1A) which was accounted for by significant increases in neutrophil recruitment (P < 0.001, Fig 1B) , and lymphocyte recruitment (P<0.05, Fig 1C) . The administration of the highly selective and competitive P2Y1 receptor antagonist MRS2500
(3mg/kg) caused a significant attenuation of LPS induced leukocyte recruitment (P<0.05, Fig   1A) , specifically neutrophil recruitment (P < 0.01, Fig 1B) , into the lungs when compared to vehicle controls. In contrast, neither administration of the specific P2Y12 antagonist (the adenosine triphosphate analogue, AR-C66096) or a P2X1 channel antagonist (the suramin analogue, NF-279) were unable to inhibit LPS induced leukocyte recruitment to the lungs (Fig   1A-C) . Administration of the prodrug of a P2Y14 antagonist (PPTN Mesylate) [33] suppressed LPS induced leukocyte recruitment (P<0.05, Fig 1A) , and specifically neutrophil recruitment (P < 0.01, Fig 1B) . Lymphocyte recruitment was also reduced by 62%, although this did not reach statistical significance (Fig 1C) .
Whilst these data demonstrating an involvement of P2Y1 receptor activation in leukocyte recruitment towards LPS is in agreement with previous data we have published in allergic inflammation [26] , we further investigated P2Y12 antagonism, since this receptor has been reported elsewhere to be involved in neutrophil inflammation [34] [35] [36] [37] . Mice were administered a second P2Y12 antagonist (Ticagrelor). However this did not lead to a suppression of pulmonary neutrophil recruitment induced by LPS at 3mg/kg or 10mg/kg Given that P2Y1, P2Y12, P2Y14, and P2X1 receptors are all expressed on platelets, and platelet activation is necessary for pulmonary leukocyte recruitment in this model of inflammation [12, 22, 27, 38] , we further examined the effects of these receptors on platelet dynamics (in vivo) and platelet-neutrophil interactions (in vitro).
Peripheral thrombocytopaenia occurs after intranasal instillation with LPS, and this is
reversed after antagonism of either the P2Y1 or P2Y14 receptors.
Peripheral thrombocytopaenia occurs during inflammation, perhaps because of localised recruitment [38] . Here, the intranasal administration of LPS lead to a significant decrease in circulating platelets at 4 hours compared to sham treated control mice (P<0.001, Fig 2) . This thrombocytopaenia induced by LPS administration was significantly reversed in mice administered either the P2Y1 antagonist (P<0. 001, Fig 2) , or the P2Y14 antagonist (P<0.01, 3B and 3C) , which was in agreement with work previously published by the authors [26] .
However, pre-incubation of platelets with the P2Y1 antagonist MRS2500 induced a significant concentration-dependent inhibition of PMN chemotaxis towards MDC (P < 0.001, Fig 3A) . As the P2Y14 receptor antagonist (PPTN) is a prodrug and requires metabolism within the liver to produce its active form, we investigated whether stimulation of platelets via P2Y14 receptors could mimic the ADP (P2Y1) -dependent platelet activation in this assay. Thus, the P2Y14 agonist UDP-glucose, and a highly specific P2Y14 agonist (MRS2690) were used to stimulate the platelet expressed P2Y14. Following incubation and stimulation of platelets with these agonists, platelet-induced PMN chemotaxis was induced to MDC (100nmol/L) in a concentration dependent manner with 1000nmol/L UDP-glucose (P<0.05; Fig 3D) or 1000nM MRS2690 (P<0.05, Fig 3E) . Levels of PMN chemotaxis were similar in these conditions to when platelets are stimulated with 100nmol/L ADP (P<0.05, Fig 3D & 3E) .
Effects of P2Y1, P2Y12, P2Y14 and P2X1 antagonist administration on haemostatic measurements in vivo and in vitro.
Given the inability of either the P2Y12 or P2X1 antagonists to effect leukocyte recruitment in response to exposure to LPS, the biological activities of AR-C66096 (P2Y12 antagonist) and NF-279 (P2X1 antagonist) were assessed by ex vivo platelet aggregation assays, and in vivo bleeding time assays. This was done to confirm that the drugs were present at effective doses, and to compare with the P2Y1 and P2Y14 antagonists that did supress LPS-induced pulmonary leukocyte recruitment. Ex vivo aggregation of platelets from mice administered LPS revealed that the possible activation of platelets by LPS had no effect on platelet aggregation towards ADP (10µmol/L) per se (Fig 4A & 4B) , yet mice administered the P2Y12 antagonist (AR-C66096) had a similarly significant reduction in platelet aggregation to those administered the P2Y1 antagonist (MRS2500) (P<0.05, Fig 4A & 4B) . However, we failed to demonstrate any effect of the P2X1 antagonist or the P2Y14 antagonist on platelet aggregation towards ADP ex vivo, as expected given the stimulus (Fig 4A & 4B) . We therefore also investigated the effect of these antagonists on in vivo bleeding times. We demonstrated that LPS challenge had no effect on bleeding times per se (Fig 4C) . Administration of the P2Y1 antagonist (MRS2500), the P2Y12 antagonist (AR-C66096) or the P2X1 antagonist (NF-279) demonstrated significant prolongation in bleeding time when compared to vehicle controls (P2Y1: P < 0.05, P2Y12: P < 0.05, P2X1: P < 0.05, Fig 4C) which in addition to the attenuation of ADP induced ex vivo platelet activation confirms their biological activity at the tested doses. In contrast, administration of 10mg/kg PPTN (P2Y14 antagonist) had no impact on bleeding times when compared to vehicle controls (Fig 4C) despite demonstrating attenuation of leukocyte recruitment following LPS challenge. Furthermore, whilst the P2Y14 agonist UDP-glucose was able to stimulate platelet-induced PMN chemotaxis towards MDC in vitro (1 µmol/L, Fig 3D) , the same concentration of this drug did not induce platelet aggregation in vitro (Fig 4D) , further suggesting that P2Y14 receptor activation does not affect haemostatic functions of platelets.
Discussion.
In this present study, we have shown that LPS induced pulmonary leukocyte recruitment in mice is dependent on P2Y1 receptor activation, in a distinct model to our previous studies where we used a murine model of allergic airways inflammation [26] . Whilst this present study has revealed that antagonism of P2Y1 receptors led to a suppression of inflammation and separately, effects on haemostasis, we have reported an apparent dichotomy in platelet P2Y1 signalling in the context of inflammation compared to haemostasis [26, 38] . Within the context of this study, it is apparent that the intranasal administration of LPS, which induced robust platelet dependent pulmonary neutrophil recruitment [12, 38] , did not affect bleeding time, or the magnitude of platelet aggregation in response to ADP ex vivo. These observations give further weight to the hypothesis that platelet activation involved in inflammation and haemostasis are not necessarily linked [40] .
For the first time, we reveal that P2Y14 receptor activation can affect platelet function by stimulating platelet-induced PMN chemotaxis (in vitro), and in the context of plateletdependent pulmonary neutrophil recruitment in vivo. However, all measured haemostatic parameters were not affected by P2Y14 in vivo. Whilst the role of platelet purinergic receptors (P2X1, P2Y1, P2Y12) in platelet aggregation has been well documented, P2Y14 has an unknown significance, with various studies suggesting that classical platelet activation is not altered [22] [23] [24] [25] 33] . P2Y14 receptors are coupled to the G protein Gi, and are activated by uridine diphosphate (UDP) and UDP-glucose [33] . Currently, signalling downstream of the P2Y14 receptor remains to be elucidated in platelets. With respect to host defence, activation of purinergic receptors also induces selectin and integrin adhesion molecule expression on the surface of leukocytes [23, 24, 32] , receptors known to be necessary for leukocyte chemotaxis [32, 41, 42] . Whilst it is not yet known whether P2Y14 has any consequence with regards to platelet function (during haemostasis, or inflammation), P2Y14 does promote RhoA-mediated signalling and chemotaxis in neutrophils [42] . Platelet shape change, filopodia formation, cytoskeletal changes and granule centralization are presumably events required to elicit platelet function during inflammatory events; nevertheless a role for Rho-GTPases in purineinduced platelet activation in the context of host defence is not yet known.
With similarities to our previous work, we were unable to provide evidence for a role for P2Y12 and P2X1 receptors in the context of LPS-induced inflammation, or P2Y12 and P2X1 dependent platelet function with respect to enhancement of neutrophil chemotaxis. We recognise that other groups have reported a role for P2Y12 receptors during a model of allergic inflammation [34] , but this is perhaps contrary to other reports stating that LPS-induced systemic inflammation is actually more severe in P2Y12 deficient mice [35] , whilst also mediating LPS induced inflammation [36] . It is also interesting to note that the P2Y12 antagonist ticagrelor may have anti-inflammatory characteristics due to effects on adenosine receptors other than P2Y12 [43] , and recently this drug has been reported to exhibit antagonism of P2Y13 [39] . Thus, the non significant trend depicting inhibition of neutrophil recruitment at the highest dose of ticagrelor tested here (30mg/kg) might involve secondary off-target effects on additional receptors involved in the inflammatory response, since in both a model of allergic airway inflammation and in this present study investigating LPS-induced lung inflammation, no other P2Y12 antagonist has displayed any potency as an anti-inflammatory agent [22] . Finally, despite our inability to show a role for P2X1 receptors in either allergic or LPS-induced inflammation, it should be noted that other groups have separately reported a role for P2X1 receptor activation in acute inflammatory events [40] .
In conclusion, we have demonstrated a role for P2Y1 and P2Y14 receptor activation in a platelet-dependent LPS induced model of neutrophil recruitment in the mouse, and that these two receptor types stimulate platelet-induced neutrophil chemotaxis in vitro.
Furthermore, the P2Y14 dependent events did not affect haemostatic measurements, whilst P2Y12 and P2X1 receptors expressed on platelets did not modulate LPS-induced inflammation. 
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